Clinical Trials Logo

Clinical Trial Summary

Colic is a term for inconsolable crying happened in the first months of life. Its etiology is multifactorial and caregiver and pediatrician generates among other problems: anxiety, risk of child abuse as well as economic costs.

There is now enough evidence for the treatment of colic using probiotics, especially Lactobacillus reuteri.

The investigators study aims to demonstrate the utility for the prevention of colic with L. reuteri and thereby avoid the problems caused by this pathology.

Objective: Compare the number of events of colic among infants with oral probiotic Lactobacillus reuteri during the first month of life versus infants with placebo

Study Design. Double blind, randomized, controlled, 492 neonates of 37-42 gestational age, breast or formula fed, will receive L. reuteri 5 drops (1x108 CFU) daily or placebo for 28 days. The investigators trial will be performed at Naval Hospital in Mexico City.


Clinical Trial Description

Methods:

This study is planned for October 2015 to October 2016 aiming newborns born population in Naval Hospital

Inclusion:

- Term Healthy Newborns (RN) ≥38 weeks and ≤ 41 weeks of gestation

- Appropriate weight for gestational age

- ≥than 8 Apgar at 5 minutes

- Egress at the first 24-48 hours of life of the newborn with the mother of hospital

- No congenital or physical abnormalities on physical examination at birth.

- Availability during the study period.

- Thorough understanding of the protocol by parents

- Informed Consent is signed by both parents.

Exclusion:

- Administration of antibiotics to the mother for a week before the birth of the newborn.

- Administration of probiotics newborn before inclusion or consumption by the mother during these last two trimesters.

- Medication Management newborn different routine prescribed at birth.

Elimination

- Loss of monitoring

- Abandonment by parents

- Diagnosis of allergy to cow's milk protein (confirmed by resolution of symptoms after switching to Formula hypo allergenic or free feeding cow's milk by the mother in breastfed children).

- Diagnosis of structural alterations or gastrointestinal illness to explain the symptoms of colic in the following months after the inclusion

Interventions:

The patients enrolled will receive probiotics (1000000000 CFU per day) or placebo every days for 28 days

Weekly, each patient will be called twice to interrogate the number of events colic as well as the different variables under study

After birth, on 15, 30, 45 and 60 of life will be cited for clinical examination and review and weight dropper bottle of probiotic

• Principal: Number of events or inconsolable crying

• Secondary: Average or evacuations / day Average or regurgitation / day Drugs to decrease excessive crying Medical reviews for excessive crying Changes feeding for excessive crying Level of satisfaction with the care of the newborn (numerical scale from 0: the worst possible, 10: completely satisfied)

• Universal variables

Weight:

Size:

Gender Weeks gestation Type of birth Feeding of formula / breast- ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT02577133
Study type Interventional
Source Hospital General Naval de Alta Especialidad - Escuela Medico Naval
Contact Héctor Javier Varona Bobadilla, Dr.
Phone (52) 55 56 24 65 00
Email kavel_555@hotmail.com
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date October 2015
Completion date October 2016

See also
  Status Clinical Trial Phase
Completed NCT01849991 - Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic Phase 1
Completed NCT01279265 - Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic N/A
Completed NCT00177086 - Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Phase 3
Recruiting NCT01715220 - Treatment of Suspected Cholelithiasis With Nitroglycerin Phase 2
Completed NCT00922727 - Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults Phase 1
Completed NCT02865564 - Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics N/A
Completed NCT01997593 - Peritoneal Ropivacaine Infiltration on Postoperative Pain in Children Affected Phase 2
Completed NCT01541046 - Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic Phase 2
Completed NCT00929292 - Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic Phase 3
Terminated NCT05554991 - Human Milk Oligosaccharide (HMO) Supplementation in Colic Management N/A
Recruiting NCT01067027 - Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri Phase 4
Recruiting NCT04983069 - Neonatal Outcome of Children With Antenatal Colic Hyperechogenicity
Recruiting NCT05685030 - Probiotics Strains for Infant Colic Phase 2
Withdrawn NCT05198700 - The Effect of Probiotics on Symptoms of Infantile Colic Phase 2
Terminated NCT02586558 - Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants N/A
Completed NCT01532518 - Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance Phase 2
Completed NCT00796523 - An Intervention to Decrease Infant Crying N/A
Completed NCT05052476 - First Line Dose-efficacy Study of Bactecal® D Liquid for Infant Colic N/A
Completed NCT02242292 - Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort Phase 2
Terminated NCT00139646 - Parecoxib in Renal Colic Phase 3